Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant contractor subpoenaed

This article was originally published in The Gray Sheet

Executive Summary

Contract manufacturer Accellent announces it has received a subpoena from the U.S. Attorney's Office in Minneapolis in a Nov. 21 8-K filing with the Securities & Exchange Commission. The subpoena, issued Oct. 28, requests documents relating to polyimide products the firm produces, which Guidant uses as an insulator for implantable cardioverter defibrillators and in other products. The New York Times has previously reported that the deterioration of this material under certain conditions might have played a role in some of the ICD malfunctions reported by the company during the past six months. The Accellent subpoena is connected with an investigation by the Attorney's Office relating to several of the firm's ICD products (1"The Gray Sheet" Oct. 31, 2005, p. 3)...
Advertisement

Related Content

Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation
Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation
Advertisement
UsernamePublicRestriction

Register

MT022953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel